Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Rhea-AI Summary

Adagene Inc. announces participation in the Leerink Partners Global Biopharma Conference 2024 to provide an update on its anti-CTLA-4 SAFEbody® ADG126 therapy, with key milestones for 2024. The Chairman, CEO, and President of R&D will present at the conference on March 12 in Miami, Florida.

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody^® ADG126, including key milestones for 2024. Company management will also host investor meetings.

Leerink Partners Global Biopharma Conference 2024

Date:	Tuesday, March 12
Presentation Time:	1:40 PM (Eastern Time)
Location:	The Fontainebleau Miami

A live webcast of the presentation will also be accessible in the Investors section of the company’s website at https://www.adagene.com. A webcast replay will be available for at least 30 days.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody^®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter.

SAFEbody^® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor & Media Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

FAQ

When is the Leerink Partners Global Biopharma Conference 2024 taking place?

The conference is scheduled for March 11-13 in Miami, Florida.

Who will provide an update on Adagene's anti-CTLA-4 SAFEbody® ADG126 therapy at the conference?

Adagene's Chairman, CEO, and President of R&D, Peter Luo, Ph.D., will provide the update.

Where can investors access the live webcast of the presentation?

Investors can access the live webcast on the company's website at https://www.adagene.com.

For how long will the webcast replay be available?

The webcast replay will be available for at least 30 days.

What are the key milestones for 2024 that will be discussed at the conference?

Key milestones for 2024 related to the masked, anti-CTLA-4 SAFEbody® ADG126 therapy will be discussed.

Who will host investor meetings during the conference?

Company management will host investor meetings.

What time is Adagene's presentation scheduled for on March 12?

The presentation is scheduled for 1:40 PM (Eastern Time) on March 12.

Where is the conference taking place?

The conference will be held at The Fontainebleau Miami.